VitaminD (2000IU/day) for 4 weeks,vitaminD plus PegIFN alfa-2a(180microgram)weekly plus ribavirin(600-1000mg/day)for 48weeks.Negative result of HCVRNA test at 12-36 weeks for 72weeks treatment(groupA)

2 trials

Sponsors

Saitama Medical University

Conditions

Chronic hepatitis C patients with genotype 1 and high viral load (&gtChronic hepatitisC patients and compensated cirrhosis patients

Unknown Phase

An open-label randomized controlled trial to assess the efficacy and safety of chronic hepatitis C patients with vitaminD plus peginterferon alpha-2a /ribavirin.versus alfacalcidol plus peginterferon alpha-2a /ribavirin.

Active, not recruitingJPRN-UMIN000004210

Saitama Medical UniversityChronic hepatitis C patients with genotype 1 and high viral load (&gt

Start: 2010-11-01Target: 40Updated: 2026-06-29

An open-label randomized controlled trial to assess the efficacy and safety of chronic hepatitis C and compensated cirrhosis patients with the prescribing pattern of vitaminD plus peginterferon alpha-2a /ribavirin.

Active, not recruitingJPRN-UMIN000008342

Saitama Medical UniversityChronic hepatitisC patients and compensated cirrhosis patients

Start: 2012-05-01Target: 80Updated: 2026-06-29